axon
injuri
critic
factor
progress
neurolog
deficit
patient
multipl
sclerosi
ms
axon
degener
may
occur
result
oligodendrocyt
death
demyelin
due
alter
trophic
support
andor
impair
mitochondri
bioenerget
recent
studi
also
indic
infiltr
leukocyt
may
directli
induc
axon
damag
revers
occur
absenc
demyelin
diseas
modifi
therapi
limit
format
extent
inflammatori
lesion
may
therefor
provid
best
approach
prevent
disabl
addit
imag
modal
identifi
injur
axon
critic
monitor
patient
respons
agent
recent
data
examin
dynam
express
chemokin
bloodbrain
barrier
bbb
indic
activ
receptor
sequest
chemokin
intracellularli
critic
entri
infiltr
leukocyt
mice
experiment
autoimmun
encephalomyel
eae
murin
model
ms
express
along
ablumin
surfac
cn
vasculatur
normal
local
infiltr
leukocyt
perivascular
space
therebi
restrict
entri
cn
loss
ablumin
specif
ms
occur
via
cytokinemedi
upregul
cn
endotheli
cell
administr
specif
antagonist
led
retent
ablumin
express
bbb
microvasculatur
prevent
patholog
entri
immun
cell
cn
parenchyma
anim
receiv
antagonist
exhibit
dosedepend
decreas
peak
diseas
sever
amelior
ongo
diseas
circumst
high
dose
antagonist
also
led
complet
clinic
recoveri
vehicl
untreat
anim
exhibit
chronic
deficit
lack
detect
clinic
deficit
anim
limit
parenchym
entri
immun
cell
support
notion
inflamm
lead
revers
axon
injuri
amelior
target
quantit
analysi
white
matter
injuri
model
ms
fraught
difficulti
due
uneven
qualiti
patholog
diffus
tensor
imag
dti
emerg
power
sensit
tool
analyz
white
matter
diseas
specif
dti
util
assess
axon
damag
demyelin
vivo
ms
anim
model
eae
dti
measur
direct
diffus
water
molecul
reflect
microstructur
organ
biolog
specimen
radial
diffus
diffus
water
perpendicular
axon
fiber
associ
myelin
integr
therefor
increas
demyelin
axial
diffus
reflect
microscop
water
movement
parallel
axon
fiber
decreas
loss
axon
integr
dti
therefor
suitabl
quantit
assess
myelin
versu
axon
injuri
preclin
studi
evalu
novel
target
treatment
ms
current
studi
util
vivo
dti
examin
axon
myelin
injuri
vehicl
versu
antagonisttr
mice
recoveri
eae
observ
axial
diffus
within
ventrolater
white
matter
vlwm
mice
treat
high
dose
antagonist
compar
mice
wherea
untreat
vehicletr
anim
show
signific
axial
diffus
reduct
suggest
axon
damag
howev
observ
chang
radial
diffus
treatment
group
suggest
antagon
impact
level
myelin
recoveri
result
valid
relev
diseas
modifi
molecul
effector
phase
eae
prevent
intraparenchym
leukocyt
migrat
also
recoveri
phase
preserv
axon
integr
moreov
result
also
support
use
dti
assess
vivo
therapeut
efficaci
treatment
cn
autoimmun
diseas
mice
jackson
lab
bar
harbor
maintain
pathogen
free
condit
depart
compar
medicin
washington
univers
st
loui
mo
studi
perform
complianc
guidelin
washington
univers
school
medicin
anim
studi
committe
antibodi
util
includ
rabbit
dako
glostrup
denmark
rat
antigfap
invitrogen
carlsbad
ca
rabbit
assay
designsenzo
life
scienc
inc
farmingdal
ny
rat
antimbp
abcam
cambridg
mous
monoclon
covanc
emeryvil
ca
igg
rabbit
rat
invitrogen
carlsbad
ca
mous
bd
pharmigen
san
diego
ca
use
isotyp
control
secondari
detect
done
use
goat
antirat
antirabbit
antimous
conjug
goat
antirabbit
antirat
conjug
molecular
probesinvitrogen
carlsbad
ca
autoreact
cell
direct
myelin
oligodendrocyt
glycoprotein
peptid
mogp
gener
previous
describ
briefli
mice
immun
genscript
piscataway
nj
mycobacterium
tuberculosi
peptid
emulsifi
freund
adjuv
difco
laboratori
detroit
mi
day
polar
cell
harvest
spleen
use
nylon
wool
column
mogreact
cell
restimul
expand
cultur
accord
standard
protocol
prior
adopt
transfer
recipi
cell
incub
stimulatorscel
obtain
splenocyt
incub
proceed
presenc
mog
gener
lab
bd
pharmigen
san
diego
ca
rpmi
enrich
media
cell
incub
day
separ
histopaqu
sigma
aldrich
saint
loui
mo
cell
restimul
stimulatorscel
day
describ
cell
underw
third
stimul
day
presenc
mog
follow
histopaqu
separ
cell
resuspend
hbss
mogreact
ul
per
mous
ratio
adopt
transfer
mogreact
cell
per
mous
done
retroorbit
recipi
mice
monitor
clinic
manifest
eae
follow
bodi
weight
grade
diseas
follow
score
system
tail
weak
difficulti
right
hind
limb
paralysi
forelimb
weak
moribund
dead
mice
underw
daili
subcutan
inject
either
vehicl
captisol
chemocentryx
mountainview
ca
dose
mgkg
bodi
weight
begin
hour
adopt
transfer
mice
per
treatment
group
cohort
mice
start
vehicl
chang
dose
mgkg
bodi
weight
achiev
score
dose
antagonist
vehicl
monitor
clinic
progress
continu
day
twenti
five
eae
mice
five
control
litterm
underw
vivo
dti
isofluraneoxygen
anesthesia
induct
mainten
deliv
custom
nose
cone
also
allow
respiratoryg
acquisit
mice
place
custom
holder
design
immobil
spine
isol
respiratori
motion
activ
detun
radiofrequ
transmit
coil
cm
intern
diamet
cm
length
use
receiv
coil
mm
intern
diamet
mm
length
design
fit
around
spine
mous
entir
prepar
place
oxford
instrument
magnet
cm
clear
bore
equip
cm
innerdiamet
activ
shield
magnex
gradient
coil
gcm
rise
time
core
temperatur
maintain
circul
warm
water
magnet
gradient
coil
gradient
power
suppli
interfac
inova
consol
varian
nmr
system
palo
alto
ca
control
sun
blade
workstat
sun
microsystem
santa
clara
ca
axial
scout
imag
spine
acquir
proper
local
spinal
cord
level
multipl
transvers
slice
cover
spinal
cord
lumbar
enlarg
obtain
use
stejskaltann
spinecho
diffus
weight
sequenc
follow
acquisit
paramet
tr
msec
determin
respiratori
rate
mous
te
msec
number
excit
equal
slice
thick
mm
spinal
cord
field
view
cm
cm
data
matrix
zerofil
diffusionsensit
gradient
appli
six
orient
gx
gy
gz
equal
gradient
strength
gcm
durat
equal
msec
separ
msec
obtain
b
valu
acquisit
time
approxim
one
hour
spinal
cord
scan
session
use
weight
linear
least
squar
method
diffus
tensor
dti
paramet
gener
studi
three
dti
paramet
map
use
rel
anisotropi
ra
axial
diffus
radial
diffus
region
interest
roi
encompass
ventrolater
white
matter
vlwm
drawn
manual
rel
anisotropi
ra
map
project
axial
radial
diffus
map
assess
axon
myelin
integr
respect
use
imagej
softwar
develop
us
nation
institut
health
avail
internet
http
rsbwebnihgovij
injur
vlwm
region
identifi
use
baselin
axial
diffus
threshold
deriv
spinal
cord
mice
murin
spinal
cord
isol
histolog
analysi
imag
briefli
anesthet
anim
intracardi
perfus
pb
fix
pfa
follow
overnight
postfix
pfa
spinal
cord
cryoprotect
sucros
prior
embed
oct
media
cryosect
lumbar
segment
identif
luxol
fast
blue
lfb
done
follow
standard
procedur
visual
zeiss
axioskop
mot
fluoresc
microscop
axiovis
softwar
carl
zeiss
intern
jena
germani
immunodetect
lymphocyt
within
cn
parenchyma
perform
via
colabel
gfap
section
lumbar
segment
spinal
cord
permeabil
block
triton
goat
serum
minut
room
temperatur
section
incub
primari
antibodi
overnight
wash
pb
incub
secondari
antibodi
minut
room
temperatur
counterstain
invitrogen
carlsbad
ca
detect
nuclei
immunostain
section
visual
zeiss
lsm
meta
confoc
laser
scan
microscop
carl
zeiss
intern
jena
germani
measur
pixel
within
roi
encompass
parenchyma
mening
done
use
public
domain
nih
imag
program
imagej
facilit
immunodetect
myelin
basic
protein
mbp
glutathion
frozen
section
lumbar
segment
submit
antigen
retriev
trypsin
cacl
tri
ph
min
section
permeabil
block
triton
goat
serum
minut
room
temperatur
primari
antibodi
incub
overnight
slide
wash
fish
skin
gelatin
pb
follow
incub
secondari
antibodi
minut
room
temperatur
wash
fish
skin
gelatin
pb
slide
nuclear
stain
dapi
invitrogen
carlsbad
ca
coverslip
vectashield
vector
laboratori
inc
burlingam
ca
visual
zeiss
axioskop
mot
fluoresc
microscop
axiovis
softwar
carl
zeiss
intern
jena
germani
immunodetect
neurofilia
h
frozen
section
lumbar
segment
permeabil
block
triton
goat
serum
minut
room
temperatur
primari
antibodi
incub
overnight
slide
wash
pb
follow
incub
secondari
antibodi
minut
room
temperatur
wash
pb
slide
nuclear
stain
invitrogen
carlsbad
ca
coverslip
shandonmount
thermo
fisher
scientif
pittsburgh
pa
visual
zeiss
lsm
meta
confoc
laser
scan
microscop
carl
zeiss
intern
jena
germani
measur
posit
signal
area
within
roi
encompass
vlwm
done
use
public
domain
nih
imag
program
imagej
statist
analysi
done
use
prism
graphpad
softwar
inc
la
jolla
ca
vivo
experi
clinic
score
dti
imag
perform
n
anim
per
treatment
group
mice
per
group
includ
histolog
studi
data
obtain
clinic
sever
score
stain
analyz
via
twoway
anova
highest
sever
score
diseas
phase
ra
map
histogram
analyz
oneway
anova
analys
follow
bonferroni
posthoc
test
correl
analysi
done
areaundercurv
auc
clinic
score
statist
analysi
p
consid
signific
recent
demonstr
antagon
amelior
eae
induc
adopt
transfer
encephalitogen
cell
decreas
leukocyt
entri
cn
parenchyma
demyelin
loss
myelin
interact
immun
neuron
cell
lead
axon
damag
wonder
whether
antagon
might
affect
extent
recoveri
mice
underw
adopt
transfer
mogreact
cell
administ
daili
inject
salin
vehicl
mgkg
specif
antagonist
monitor
diseas
progress
period
day
order
examin
whether
limit
inflammatori
infiltr
ongo
diseas
impact
recoveri
half
vehicletr
mice
began
administr
attain
clinic
score
consist
previou
report
antagon
led
dose
depend
decreas
peak
sever
eae
even
mice
establish
diseas
figur
evalu
diseas
sever
recoveri
phase
day
posttransf
blue
bracket
figur
reveal
mice
exhibit
dosedepend
increas
recoveri
significantli
lower
clinic
sever
score
vehicl
salinetr
control
group
tabl
figur
anim
group
exhibit
highest
sever
score
recoveri
phase
day
posttransf
figur
recoveri
phase
vehicl
salin
sem
interest
anim
treat
attain
clinic
score
exhibit
mean
sever
score
upon
recoveri
phase
day
posttransf
blue
bracket
figur
began
treatment
time
adopt
transfer
despit
signific
differ
peak
clinic
diseas
sever
effector
phase
day
posttransf
red
bracket
figur
figur
twoway
anova
interact
f
dfn
dfd
p
antagonist
treatment
f
dfn
dfd
p
day
postadopt
transfer
f
dfn
dfd
p
figur
twoway
anova
interact
f
p
diseas
phase
f
p
treatment
f
p
tabl
oneway
anova
effector
phase
f
p
tabl
oneway
anova
recoveri
phase
f
p
data
suggest
antagon
modifi
diseas
sever
eae
enhanc
overal
recoveri
regardless
initi
impair
access
via
clinic
score
vivo
dti
perform
assess
microstructur
chang
within
multipl
transvers
slice
lumbar
enlarg
mous
spinal
cord
figur
vehicl
salinetr
mice
recoveri
peak
eae
plu
agematch
control
mice
rel
anisotropi
ra
map
gener
within
manual
defin
region
interest
roi
vlwm
figur
axon
myelin
injuri
vlwm
sever
control
group
appar
eae
mice
evidenc
intens
chang
radial
axial
diffus
map
figur
statist
analysi
chang
radial
diffus
fail
show
signific
differ
vlwm
among
studi
group
suggest
differ
myelin
integr
figur
oneway
anova
f
p
contrast
analysi
chang
vlwm
axial
diffus
detect
signific
decreas
group
mice
receiv
low
dose
mgkg
vehicl
salin
versu
receiv
high
dose
mgkg
mice
figur
axial
diffus
mgkg
mice
resembl
valu
group
mgkg
mice
resembl
obtain
control
group
figur
oneway
anova
f
p
lastli
ra
vlwm
show
differ
vehicl
salinetr
mice
mice
figur
oneway
anova
f
p
extent
axon
preserv
assess
accord
axial
diffus
distribut
spinal
cord
figur
distinguish
injur
normal
appear
vlwm
figur
differ
extent
injur
vlwm
detect
mgkg
mice
mgkg
vehicl
salinetr
mice
exhibit
gradat
injuri
within
vlwm
figur
next
inquir
chang
axial
diffus
treatment
correl
diseas
recoveri
answer
question
evalu
mean
clinic
score
recoveri
phase
day
postadopt
transfer
function
axial
diffus
vlwm
injur
vlwm
analys
show
statist
signific
linear
correl
clinic
score
recoveri
phase
axial
diffus
figur
f
dfn
dfd
p
injur
vlwm
figur
f
dfn
dfd
p
addit
linear
correl
temporalcumul
clinic
score
injur
vlwm
time
dti
evalu
signific
figur
f
dfn
dfd
p
data
strongli
support
role
diseasemodifi
molecul
recoveri
phase
eae
via
axon
preserv
prior
studi
evalu
effect
antagon
eae
reveal
decreas
demyelin
mice
treat
compar
vehicletr
anim
peak
diseas
observ
differ
measur
radial
diffus
treatment
group
diseas
recoveri
perform
luxol
fast
blue
lfb
stain
spinal
cord
lumbar
segment
consist
dti
data
appar
differ
treatment
group
vlwm
myelin
densiti
detect
method
figur
interest
mice
treat
mgkg
exhibit
myelindens
stain
compar
anim
figur
upper
panel
day
postadopt
transfer
persist
inflamm
still
detect
within
vlwm
spinal
cord
salin
vehicletr
mice
extent
mice
treat
mgkg
mice
treat
mgkg
figur
lower
panel
versu
middl
right
upper
panel
also
observ
patholog
featur
consist
hypertroph
degener
axon
bundl
report
human
rodent
model
cn
degener
trauma
figur
lower
panel
arrowhead
howev
featur
absent
mgkg
mice
normal
appear
axon
present
figur
midupp
panel
arrow
better
assess
myelin
protein
express
oligodendrocyt
number
examin
myelin
basic
protein
mbp
immunoreact
mbp
express
frequent
use
immunohistochem
analysi
demyelin
remyelin
eae
marker
matur
oligodendrocyt
consist
lfb
stain
mbp
express
immunoreact
within
vlwm
compar
among
treatment
group
note
mbp
stain
exhibit
heterogen
within
spinal
cord
mice
eae
receiv
higher
dose
antagonist
find
suggest
antagon
preserv
axon
independ
myelin
recoveri
assess
phenotyp
immun
cell
persist
within
cn
parenchyma
recoveri
spinal
cord
tissu
five
treatment
group
control
evalu
mening
parenchym
cell
conjunct
gfap
express
latter
delin
mening
parenchym
border
treatment
group
exhibit
mening
cell
increas
number
vehicl
salinetr
mice
compar
mice
treat
mgkg
mgkg
figur
parenchym
infiltr
cell
also
increas
vehicl
salinetr
mice
compar
mice
treat
exhibit
parenchym
cell
figur
quantit
analysi
mening
parenchym
stain
within
parenchyma
mening
mice
treatment
group
reveal
signific
differ
two
cn
region
mice
treat
low
dose
mgkg
vehicl
salinetr
control
mice
treat
high
dose
mgkg
figur
twoway
anova
interact
f
dfn
dfd
p
antagonist
treatment
f
dfn
dfd
p
area
cn
parenchyma
mening
f
dfn
dfd
p
comparison
stain
within
spinal
cord
parenchyma
mening
across
treatment
group
reveal
highli
signific
differ
treatment
group
vehicletr
control
tabl
oneway
anova
parenchyma
f
p
data
indic
antagon
prevent
persist
cell
infiltr
within
spinal
cord
parenchyma
could
potenti
contribut
ongo
axon
damag
order
assess
content
spare
spinal
cord
vlwm
treatment
group
recoveri
eae
spinal
cord
section
encompass
segment
use
lfb
stain
examin
extent
neurofila
h
nfh
dephosphoryl
via
immunofluoresc
previous
report
immunoposit
found
predominantli
neuron
cell
bodi
littl
detect
stain
white
matter
group
mgkg
mice
anim
figur
upper
panel
similar
pattern
observ
mgkg
mice
group
figur
left
lower
panel
extens
immunoreact
howev
detect
spinal
cord
vlwm
either
salin
vehicletr
mice
even
area
myelin
present
figur
middl
right
lower
panel
consist
dti
find
axon
damag
figur
middl
right
lower
panel
statist
analys
pixelsarea
within
dorsal
later
ventral
spinal
cord
white
matter
mice
treatment
group
reveal
signific
decreas
versu
control
anim
within
later
ventral
region
figur
anova
interact
f
dfn
dfd
p
antagonist
treatment
f
dfn
dfd
p
white
matter
area
f
dfn
dfd
p
data
support
dti
find
antagon
set
eae
prevent
axon
damag
dose
depend
fashion
current
studi
util
vivo
dti
evalu
role
recoveri
eae
provid
compel
evid
antagon
prevent
inflammatorymedi
injuri
axon
axial
diffus
measur
injur
spinal
cord
vlwm
mice
treat
antagonist
undistinguish
mice
significantli
differ
vehicl
salinetr
mice
consist
extens
immunoreact
within
spinal
cord
vlwm
detect
salin
vehicletr
mice
tissu
obtain
mice
treat
antagonist
contrast
differ
radial
diffus
measur
extent
lfb
stain
mbp
immunoreact
group
suggest
axon
preserv
set
antagon
may
independ
myelin
repair
linear
correl
injur
vlwm
mean
maxim
diseas
sever
score
observ
recoveri
phase
consist
notion
immunemedi
axon
damag
persist
late
stage
eae
controltr
anim
consist
observ
signific
increas
persist
inflammatori
infiltr
within
parenchyma
salin
vehicletr
mice
abrog
administr
control
tissu
also
exhibit
presenc
patholog
featur
consist
hypertrophicdegen
axon
bundl
suggest
axon
damag
lack
myelin
key
patholog
mice
chronic
deficit
find
support
relev
antagonist
treatment
preserv
axon
integr
indic
dti
may
use
determin
treatment
effect
small
molecul
inhibitor
patholog
biomark
cn
autoimmun
grow
bodi
evid
support
notion
neurolog
dysfunct
ms
occur
result
axon
degener
may
depend
occur
independ
chronic
demyelin
demyelinationdepend
mechan
includ
ongo
axon
toxic
due
upregul
sodium
channel
throughout
length
demyelin
axon
ms
eae
consist
mice
defici
na
channel
subunit
exhibit
decreas
axon
degener
loss
eae
compar
wildtyp
anim
despit
similar
level
cn
inflamm
howev
myelin
axon
segment
continu
expos
activ
macrophag
product
undergo
focal
degener
associ
mitochondri
dysfunct
suggest
inflammatori
mediat
may
induc
axon
damag
without
demyelin
consist
use
biozzi
abh
murin
model
jackson
colleagu
demonstr
axon
patholog
primari
event
relapsingprogress
eae
investig
observ
axon
loss
acut
phase
diseas
prior
demyelin
axon
loss
absenc
chronic
inflamm
relaps
studi
vehicletr
mice
ongo
diseas
could
attain
complet
recoveri
upon
initi
antagonist
suggest
peak
diseas
contain
revers
compon
group
exhibit
equal
level
radial
axial
diffus
revers
may
attribut
axon
damag
previou
work
demonstr
antagon
decreas
infiltr
immun
cell
cn
parenchyma
assess
immunohistochemistri
flow
cytometri
thu
cell
entri
like
primari
event
revers
injur
axon
consist
cell
reportedli
caus
bystand
axon
damag
murin
cerebellar
slice
cultur
anoth
put
mechan
cellmedi
axon
dysfunct
via
microtubul
destabil
observ
caus
synapt
impair
accumul
app
aggreg
studi
util
antagonist
ongo
address
possibl
mechan
recent
studi
indic
oligodendrocyt
precursor
cell
opc
express
receptor
essenti
remyelin
thu
possibl
antagon
impact
opc
biolog
although
eaerecov
vehicl
versu
antagonisttr
mice
exhibit
equival
level
myelin
assess
dti
lfb
stain
mbp
immunohistochem
analys
detect
new
myelin
may
better
accomplish
use
nonimmunemedi
model
demyelin
cuprizon
toxic
mice
fed
copper
chelat
cuprizon
display
specif
demyelin
corpu
callosum
exhibit
remyelin
upon
cessat
toxin
studi
examin
antagon
context
may
conduc
evalu
opc
recruit
matur
altern
antagon
previous
shown
limit
demyelin
peak
eae
possibl
preserv
axon
integr
due
preserv
myelin
prior
studi
reveal
strong
correl
chang
axial
diffus
white
matter
patholog
via
quantit
pixelwis
dti
analysi
strengthen
use
axial
diffus
biomark
axon
integr
nevertheless
sever
studi
demonstr
efficaci
dti
evalu
vivo
treatment
modal
anim
model
cn
injuri
first
studi
evalu
pharmacolog
inhibitor
murin
model
ms
vivo
mi
et
al
show
treatment
spraguedawley
rat
promot
recoveri
moginduc
eae
either
intrathec
system
deliveri
investig
also
correl
eae
amelior
axon
integr
assess
axial
diffus
howev
imag
perform
postmortem
fix
spinal
cord
specimen
recent
dti
use
success
patient
evalu
gcsf
treatment
amyotroph
later
sclerosi
antitubercular
treatment
tubercul
mening
highlight
feasibl
dti
evalu
cn
lesion
inflamm
summari
studi
provid
evid
antagon
set
cn
autoimmun
prevent
axon
loss
assess
novel
imag
standard
histolog
modal
addit
work
support
use
dti
especi
axial
diffus
noninvas
biomark
detect
axon
integr
eae
ms
author
declar
compet
interest
lco
rsk
design
research
wrote
paper
lco
yjc
dd
jhk
conduct
research
acquisit
data
analysi
interpret
data
sk
rsk
analysi
interpret
data
author
read
approv
final
manuscript
